Co-Target(s) Information
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T75797 | Target Info | |||
| Target Name | Prostaglandin F2-alpha receptor (PTGFR) | ||||
| Synonyms |
Prostanoid FP receptor; PGF2-alpha receptor; PGF2 alpha receptor; PGF receptor; FP prostanoid receptor; FP prostaglandin receptor
Click to Show/Hide
|
||||
| Target Type | Successful Target | ||||
| Gene Name | PTGFR | ||||
| Biochemical Class | GPCR rhodopsin | ||||
| UniProt ID | |||||
| Co-Targets of This Target | Top | |||||
|---|---|---|---|---|---|---|
| Co-Target Name | Thromboxane A2 receptor (TBXA2R) | Successful Target | ||||
| UniProt ID | TA2R_HUMAN | |||||
| Gene Name | TBXA2R | |||||
| Synonyms |
TXA2-R; TXA2 receptor; Prostanoid TP receptor
Click to Show/Hide
|
|||||
| Representative Drug(s) | PGF2alpha | Drug Info | IC50 ~ 0.001 nM | Click to Show More | [1] | |
| 2 | LAROPIPRANT | Drug Info | Ki = 2.95 nM | [3] | ||
| Co-Target Name | Prostaglandin E2 receptor EP2 (PTGER2) | Successful Target | ||||
| UniProt ID | PE2R2_HUMAN | |||||
| Gene Name | PTGER2 | |||||
| Synonyms |
Prostanoid EP2 receptor; Prostaglandin E2 receptor EP2 subtype; PGE2 receptor EP2 subtype; PGE receptor, EP2 subtype; PGE receptor EP2 subtype; EP2 receptor
Click to Show/Hide
|
|||||
| Representative Drug(s) | Dinoprostone | Drug Info | Ki = 1.03 nM | Click to Show More | [2] | |
| 2 | LAROPIPRANT | Drug Info | Ki = 136 nM | [3] | ||
| Co-Target Name | Prostacyclin receptor (PTGIR) | Successful Target | ||||
| UniProt ID | PI2R_HUMAN | |||||
| Gene Name | PTGIR | |||||
| Synonyms |
Prostanoid IP receptor; Prostaglandin I2 receptor; PRIPR; PGI2 receptor; PGI receptor; IP prostanoid receptor
Click to Show/Hide
|
|||||
| Representative Drug(s) | Dinoprostone | Drug Info | IC50 = 260 nM | [4] | ||
| Co-Target Name | Prostaglandin E2 receptor EP4 (PTGER4) | Clinical trial Target | ||||
| UniProt ID | PE2R4_HUMAN | |||||
| Gene Name | PTGER4 | |||||
| Synonyms |
Prostanoid EP4 receptor; Prostaglandin E2 receptor EP4 subtype; PTGER2; PGE2 receptor EP4 subtype; PGE receptor EP4 subtype
Click to Show/Hide
|
|||||
| Representative Drug(s) | Dinoprostone | Drug Info | EC50 = 0.02 nM | [2] | ||
| Co-Target Name | Prostaglandin D2 receptor (PTGDR) | Clinical trial Target | ||||
| UniProt ID | PD2R_HUMAN | |||||
| Gene Name | PTGDR | |||||
| Synonyms |
Prostanoid DP receptor; PGD2 receptor; PGD receptor
Click to Show/Hide
|
|||||
| Representative Drug(s) | LAROPIPRANT | Drug Info | IC50 = 0.09 nM | [3] | ||
| Co-Target Name | Prostaglandin E2 receptor EP3 (PTGER3) | Clinical trial Target | ||||
| UniProt ID | PE2R3_HUMAN | |||||
| Gene Name | PTGER3 | |||||
| Synonyms |
Prostanoid EP3 receptor; Prostaglandin E2 receptor EP3 subtype; PGE2-R; PGE2 receptor EP3 subtype; PGE receptor, EP3 subtype; PGE receptor EP3 subtype
Click to Show/Hide
|
|||||
| Representative Drug(s) | Dinoprostone | Drug Info | Ki = 0.33 nM | Click to Show More | [5] | |
| 2 | PGF2alpha | Drug Info | IC50 = 110 nM | [1] | ||
| 3 | LAROPIPRANT | Drug Info | Ki = 892 nM | [3] | ||
| Co-Target Name | Prostaglandin E2 receptor EP1 (PTGER1) | Clinical trial Target | ||||
| UniProt ID | PE2R1_HUMAN | |||||
| Gene Name | PTGER1 | |||||
| Synonyms |
Prostanoid EP1 receptor; Prostaglandin E2 receptor EP1 subtype; PGE2 receptor EP1 subtype; PGE receptor, EP1 subtype; PGE receptor EP1 subtype; EP1 receptor
Click to Show/Hide
|
|||||
| Representative Drug(s) | Dinoprostone | Drug Info | IC50 = 1.1 nM | Click to Show More | [6] | |
| 2 | PGF2alpha | Drug Info | IC50 = 220 nM | [1] | ||
| Co-Target Name | Prostaglandin D2 receptor 2 (PTGDR2) | Clinical trial Target | ||||
| UniProt ID | PD2R2_HUMAN | |||||
| Gene Name | PTGDR2 | |||||
| Synonyms |
PTGDR2; Chemoattractant receptor-homologous molecule expressed on Th2 cells; CD294
Click to Show/Hide
|
|||||
| Representative Drug(s) | LAROPIPRANT | Drug Info | Ki = 745 nM | [3] | ||
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Synthesis and biological evaluation of prostaglandin-F alkylphosphinic acid derivatives as bone anabolic agents for the treatment of osteoporosis. J Med Chem. 2001 Nov 22;44(24):4157-69. | ||||
| REF 2 | Difluoromethylene at the gamma-Lactam alpha-Position Improves 11-Deoxy-8-aza-PGE 1 Series EP 4 Receptor Binding and Activity: 11-Deoxy-10,10-difluoro-8-aza-PGE 1 Analog (KMN-159) as a Potent EP 4 Agonist. J Med Chem. 2019 May 9;62(9):4731-4741. | ||||
| REF 3 | Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806. | ||||
| REF 4 | Prostanoid receptor EP2 as a therapeutic target. J Med Chem. 2014 Jun 12;57(11):4454-65. | ||||
| REF 5 | Synthesis and evaluation of a gamma-lactam as a highly selective EP2 and EP4 receptor agonist. Bioorg Med Chem Lett. 2008 Jan 15;18(2):821-4. | ||||
| REF 6 | Emerging targets in osteoporosis disease modification. J Med Chem. 2010 Jun 10;53(11):4332-53. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.